The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Aaron Simmons
Project Title: Naturalistic Driving Dynamics, Multimodal Neuroimaging, and Longitudinal Clinical Progression in the DRIVES Project
Date: September 5, 2026 at 2:31 am
Request ID:
Aim 1: Derive reproducible participant-level markers from low- and high-frequency naturalistic driving data collected during March-May 2023, including mobility, speed, braking, acceleration, idling, and within-trip kinematic variability.
Aim 2: Test associations of driving markers with structural MRI burden and longitudinal change in hippocampal volume, AD-signature cortical thickness, and white matter hyperintensities using all available imaging time points.
Aim 3: Determine whether driving markers are associated with amyloid and tau PET burden and longitudinal accumulation using all available PET time points, accounting for demographics, driving exposure, and assessment timing.
Aim 4: Evaluate whether driving dynamics add information beyond conventional trip summaries and clinical measures for subsequent cognitive-functional decline and diagnostic progression, using the complete available clinical follow-up.
Investigator: Asim Iqbal
Project Title: External Validation of MRI-to-Neuropathology and Molecular Prediction Models in Alzheimer Disease
Date: September 4, 2026 at 12:46 pm
Request ID:
Aim 1: Identify Knight ADRC participants with overlapping antemortem structural MRI and postmortem neuropathology and harmonize anatomically and biologically comparable features with SEA-AD.
Aim 2: Evaluate whether MRI-to-neuropathology relationships learned from SEA-AD generalize to an independent longitudinal Alzheimer disease cohort.
Aim 3: Determine the overlap of MRI and neuropathology participants with available brain molecular/omics data to assess feasibility of an MRI to neuropathology to molecular prediction framework.
Aim 4:
Investigator: Richard Mayeux
Project Title: Autopsy results heterogeneity among siblings and related family members on the AD Family Based Study
Date: September 4, 2026 at 10:42 am
Request ID:
Aim 1: Autopsy report harmonization across different institutions and pathologist
Aim 2: Analyze heterogeneity among siblings and related family members
Aim 3:
Aim 4:
Investigator: Wang wei
Project Title: CSF DKK3 Across the Alzheimer Disease Biological Continuum: Associations with AT(N), Neuroimaging, and Longitudinal Cognition
Date: September 3, 2026 at 1:12 am
Request ID:
Aim 1: Determine whether CSF DKK3 is associated with Alzheimer disease biological stage and continuous amyloid, tau, and neurodegeneration biomarkers.
Aim 2: Evaluate associations of CSF DKK3 with amyloid and tau PET, structural MRI measures, and matched fluid biomarkers when available.
Aim 3: Determine whether baseline CSF DKK3 is associated with longitudinal cognitive decline and clinical progression across the Alzheimer disease continuum.
Aim 4: Assess the robustness and specificity of DKK3 associations across demographic, APOE, biomarker-defined, and clinical subgroups using the broader CSF proteomic context.
Investigator: Ke Hou
Project Title: Plasma Biomarker Models for Alzheimer’s Disease Pathology, Tau Staging, Clinical Progression, and eMTBR-tau243 Prediction
Date: August 31, 2026 at 8:59 pm
Request ID:
Aim 1: To develop models for predicting plasma eMTBR-tau243 from widely available plasma biomarkers and clinical variables, enabling estimation of tau-related pathology when direct eMTBR-tau243 measurement is unavailable.
Aim 2: To develop and validate plasma biomarker models for identifying cerebral amyloid pathology, using amyloid PET measures as the reference standard.
Aim 3: To characterize biological stages of Alzheimer’s disease by integrating plasma eMTBR-tau243 with amyloid and tau pathology and to evaluate its utility for blood-based tau staging.
Aim 4: To develop longitudinal models for predicting cognitive decline and progression to symptomatic Alzheimer’s disease using plasma biomarkers, demographics, genetics, and baseline disease stage.
Investigator: Jun Yang
Project Title: Plasma and CSF SEPHS1 as Compartment-Specific Markers of Cognitive Trajectory in Alzheimer Disease
Date: August 28, 2026 at 2:19 pm
Request ID: D2659
Aim 1: Determine whether plasma SEPHS1 protein abundance is associated with Alzheimer disease biomarkers, clinical status, and cognitive function.
Aim 2: Determine whether baseline plasma SEPHS1 predicts subsequent cognitive-functional decline and clinical progression.
Aim 3: Determine plasma–CSF SEPHS1 concordance and whether plasma and CSF SEPHS1 provide independent information about longitudinal cognitive outcomes.
Aim 4:
Investigator: Tammie Benzinger
Project Title: Prediction of Alzheimer’s Disease Dementia Using Lateral Ventricular Volume and Plasma p-tau217
Date: August 27, 2026 at 1:19 pm
Request ID: D2658
Aim 1: Evaluate whether the combination of baseline LVV and plasma p-tau217 provides prediction of incident AD dementia.
Aim 2: Evaluate whether longitudinal changes in LVV and plasma p-tau217 are associated with incident AD dementia and clinical progression.
Aim 3:
Aim 4:
Investigator: Strain
Project Title: Evaluating the composition of WMH spatial distribution using Quantitative gradient echo MRI
Date: August 26, 2026 at 5:51 pm
Request ID: D2657
Aim 1: 1. Is the qGRE signal different across different WMH topographies?
Aim 2: 2. Does the combination of qGRE and WMH spatial location better associate with known etiologies.
Aim 3:
Aim 4:
Investigator: John-Paul J. Yu, MD, PhD
Project Title: Cross-Cohort Generalization of STRATA, an MRI-Based Cellular Deconvolution Methodology, Across the Alzheimer’s Disease Continuum: Validation in the Knight ADRC/KARI Dataset
Date: August 25, 2026 at 11:21 am
Request ID: D2656
Aim 1: Determine whether STRATA-predicted hippocampal neuronal and glial (astrocyte, microglia, oligodendrocyte) proportions differ across cognitively unimpaired, MCI-AD, and AD-dementia participants in the Knight ADRC/KARI cohort, replicating our Wisconsin ADRC findings.
Aim 2: In the subset of KARI participants with longitudinal diffusion MRI, determine whether STRATA-predicted cell-type proportions change over time, replicating our longitudinal delta-score analyses of the Wisconsin ADRC/WRAP cohorts.
Aim 3: Determine whether STRATA-predicted hippocampal cell-type proportions are associated with amyloid-PET, tau-PET, and CSF biomarkers in the Knight ADRC/KARI cohort.
Aim 4: Determine whether STRATA-predicted hippocampal cell-type proportions are associated with cognitive performance, indexed by the PACC composite, across the Alzheimer’s disease continuum in the Knight ADRC/KARI cohort.
Investigator: Matthew R. Brier
Project Title: Immune Mechanisms of Amyloid-β Protection in Multiple Sclerosis: NULISAseq Proteomic Profiling of Non-MS Knight ADRC Controls
Date: August 24, 2026 at 11:52 am
Request ID: D2655
Aim 1: Determine whether MS modifies the plasma proteomic signature of Aβ pathology.
Aim 2: Test whether cumulative DMT exposure reduces AD biomarker burden.
Aim 3:
Aim 4: